Moreover, RNA profiles in TEPs enabled to discriminate patients with localized and metastasized cancer from healthy controls, even precisely pinpoint the primary origin of pan-cancer, as well as predict the oncogenic status including MET or HER2 positivity and the existence of KRAS, EGFR, or PIK3CA mutations (10). This evidence concerns the gene KRAS and cancer.